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Summary  
 
Anaesthesia with S (+) ketamine results in better recoveries in humans, cats and horses 
than with racemic ketamine at dose rates of only 50-66% of the racemic ketamine. 
This prospective, blinded, randomized trial compared anesthesia induction with 
intravenous S (+) ketamine (2 mg/kg, n= 20) and racemic ketamine (4 mg/kg, n=20) in 
40 dogs undergoing castration. Sedation was performed with intramuscular 
medetomidine and butorphanol in both groups. For analgesia lidocaine was applied 
locally. Anaesthesia was monitored as under clinical circumstances. Sixty minutes after 
S (+) or racemic ketamine atipamezole was administered and recovery quality assessed 
with standardized scores 0, 10, 20, 30, and 60 minutes thereafter.  
During the intraoperative phase, three dogs in the S (+) ketamine group needed an extra 
bolus of intravenous S (+) ketamine to maintain adequate anaesthesia depth. Another 
two dogs, one in each group, showed spasms immediately post-operatively which 
needed treatment and were excluded from comparison. Respiration was better 
maintained with S (+) ketamine. Recovery was not different between the groups.  
Half dose of S (+) ketamine provided similar anaesthesia quality, cardiopulmonary 
function and recovery as racemic ketamine. Only dogs with S (+) ketamine needed 
redosing to finish the surgery. This might suggest that duration of action of S (+) 
ketamine is slightly less than that of racemic ketamine, as has been suggested in other 
species.  
 
 
Keywords: Dogs, S (+) ketamine, racemic ketamine, anaesthesia induction, recovery 
5 
 
1. Introduction 
Ketamine is a non-competitive glutamate N-methyl-D-aspartate (NMDA) receptor 
antagonist (Anis et al., 1983) used in human and veterinary anaesthesia, which is 
composed of two optical isomers in a 50:50% racemic mixture (Kharasch and Labroo, 
1992; Kharasch et al., 1992). The 2 isomers present in the racemic mixture have 
different pharmacodynamic and pharmacokinetic properties. The levorotatory 
enantiomer, S (+) ketamine, has potential advantages as compared to the dextrorotatory 
enantiomer and to the racemic mixture including: a) a stronger anaesthetic effect (White 
et al., 1985), b) a quicker recovery from anaesthesia (Doenicke et al., 1992; White et al., 
1985), c) reduction of uncontrolled locomotor activity during recovery (White et al., 
1985), and d) a more advantageous profile regarding cardiovascular side effects (Graf 
et al., 1995). This is why the use of S (+) ketamine has gained wide acceptance in 
human medicine, and much effort are being undertaken to explore more precisely its 
properties in veterinary medicine.  
S (+) ketamine is currently registered in Switzerland for feline use only. The 
pharmaceutical company Dr. E. Graeub AG is the first company to register the S (+) 
ketamine under the trade name Keta S ®, ad us vet. In cats undergoing elective 
orchiectomy, S (+) ketamine provided faster recovery from anaesthesia than racemic 
ketamine with only 60% of the racemic dose. In this study, postoperative analgesia was 
considered similar for both formulations. S (+) ketamine has also been successfully 
used in ASA III cat patients offering a significantly faster recovery as compared to the 
racemic mixture (Larenza et al., 2008). Post-operative analgesia and recovery quality 
were judged significantly better in this study as well. 
A recent pharmacokinetic study conducted in dogs showed that S (+) ketamine has a 
higher plasmatic clearance as compared to the R (-) isomer and to the racemic form 
(Henthorn et al., 1999). That might explain why the anaesthetic recovery is faster in 
patients anaesthetised with S (+) ketamine. In assays testing the equipotency of 
different ketamines in dogs, quality and length of anaesthesia were similar after IV 
injection of 10 mg/kg of racemic ketamine or 6.6 mg/kg of S (+) ketamine (Deleforge et 
al., 1991). In contrast, another study performed in dogs that received IV racemic 
ketamine at 9 mg/kg or S (+) ketamine at 6 mg/kg, showed that all anaesthetic periods 
were longer for dogs treated with racemic ketamine (Duque et al., 2008). In regard to 
cardiovascular function, previous studies performed in dogs using equivalent doses of 
racemic or S (+) ketamine did not show differences in the cardiopulmonary effects 
induced by 30 mg/kg IV of either compound (Muir and Hubbell, 1988). Similarly, 
comparable electrophysiological effects after 20 mg/kg of either drug were observed and 
it was concluded that both formulations have very similar effects on cardiac electrical 
conductivity (Souza et al., 2002). 
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However, to date there are no clinical reports comparing S (+) and the racemic form of 
ketamine using equipotent doses in dogs. Previous studies used equivalent doses and 
results were not conclusive.  
Therefore, the present study was designed to compare the anaesthetic properties of two 
doses of racemic and S (+) ketamine in canine patients undergoing an elective surgical 
procedure. 
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2. Literature 
 
2.1 Isomerism 
2.1.1 Discovery of Isomers 
In 1812, Jean-Baptiste Biot studied the polarisation of light passing through chemical 
solutions and presented a comprehensive theory showing how crystalline solids and 
samples containing an excess of one enantiomer of a chiral molecule rotate the 
orientation of plane-polarised light. He discovered chirality in 1832 by observing the 
ability of a tartaric acid solution to rotate polarised light.  
In 1828 Joseph Louis Gay-Lussac coined the name racemic acid (acide racémique, 
from the Latin racemus, for a bunch of grapes) to describe the para-tartaric acid and 
demonstrated that this racemate had the same chemical composition as tartaric acid.  
Louis Pasteur, made a series observations involving solutions of tartaric acid (from the 
tartar deposits in maturing barrels of wine (Fig. 1) and a second form of this acid, known 
as para-tartaric acid. Pasteur noted that the two crystals were mirror images of each 
other. Pasteur manually separated these crystals and noted that the separate solutions, 
with equivalent concentrations of tartaric acid crystals, rotated in linearly polarised light 
in equal but opposite directions. In addition, when equal parts of the two tartaric acid 
solutions were combined, no optical rotation was observed. From this observation, 
Pasteur inferred that the optically inactive racemic acid was composed of equal amounts 
of (+) and (−) enantiomers of tartaric acid (Louis Pasteur). 
 
 
 
  
 
Levotartaric acid 
R (−) tartaric acid  
 
Dextrotartaric acid 
S (+) tartaric acid 
 
 
 
 
Fig.1: Tartar deposits in maturing barrels of wine and tartaric acid (racemic acid) when in 1:1 ratio, 
chemical formulas of the 2 compounds 
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2.1.2 Definitions 
Enantiomer is one of two stereoisomers that are non-super imposable mirror images 
(Fig. 2) of each other. They are compared with one's left and right hands, with the same 
shape but opposite.  
 
Fig. 2: Example of 2-aminopropanoic acid (alanine) 
 
 
Stereoisomers are isomeric molecules that have the same molecular formula and 
sequence of bonded atoms (constitution), but which differ in the three dimensional 
orientations of their atoms in the space. 
Isomers are compounds with the same molecular formula but have different structural 
formulae. 
Racemate or racemic mixture is a compound that has equal amounts of left- and right-
handed enantiomers of a chiral molecule. 
2.1.3 Structural Isomerism  
There are 3 forms of structural isomerism: 
Position isomerism 
Position isomers have a functional group in a different position on the chain (Fig. 3). 
Skeletal isomerism 
In skeletal isomerism, or chain isomerism, components of the skeleton are distinctly re-
ordered to create different structures. For example (Fig. 3) 3-methylpentane is a chain 
isomer of 2-methylpentane
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Tautomerism 
Tautomerism is a special case of structural isomerism. Tautomers are organic 
compounds that are interconvertible (Fig. 4) by a chemical reaction called 
tautomerisation. In solutions where tautomerisation is possible, a chemical equilibrium of 
the tautomers will be reached. The exact ratio of the tautomers depends on several 
factors, including temperature, solvent, and pH. 
 
 
 
 
 
 
 
 
Fig. 3: Methylpenthane 
 
 
 
Fig. 4: Tautermer examples 
 
 
2.1.4 Different types of isomerism 
Stereoisomerism can be distinguished in geometrical and optical isomerism. 
2.1.4.1 Geometrical isomerism 
Also known as cis-trans isomerism geometrical is a form of stereoisomerism. Also 
known as Z (from the German zusammen, together or if they are on opposite sides it is 
E (from the German entgegen, opposite). Dichloroethene illustrate an example for 
geometrical isomerism (Fig. 5) 
 
 
 
 
 
Fig. 5:  An example of double bond stereoisomerism is 1,2-dichloroethene, 
C2H2Cl2.Molecule I is Z-1,2-dichloroethene and molecule II is E-1,2-
dichloroethene. 
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2.1.4.2 Optical isomerism 
Optical isomers are named like this because of their effect on plane polarised light. 
Simple substances, which show optical isomerism, exist as two isomers known as 
enantiomers. 
A solution of one enantiomer rotates the plane of polarisation in a clockwise direction. 
This enantiomer is known as the (+) form or dextrorotatory isomer. 
For example, one of the optical isomers (enantiomer) of the amino acid alanine is known 
as (+) alanine. 
A solution of the other enantiomer rotates the plane of polarisation in an anti-clockwise 
direction. This enantiomer is known as the (-) form or levorotatory isomer. So the other 
enantiomer of alanine is known as or (-) alanine. 
If the solutions are equally concentrated, the amount of rotation caused by the two 
isomers is exactly the same but in opposite directions. 
When optically active substances are made in the lab, they often occur as a 50/50 
mixture of the two enantiomers. This is known as a racemic mixture or racemate. It has 
no effect on plane-polarised light. 
2.1.5 Nomenclature 
Two principal systems of nomenclature have been developed to describe the absolute 
configuration of asymmetric molecules. According to the first convention (Fisher), two 
reference compounds, the natural levorotatory enantiomer of serine (designated L-
serine) and the natural dextrorotatory enantiomer of glyceraldehydes (designated D-
glyceraldehyde). On the other hand, a second convention introduced by Cahn et al 
(1956), is based on a set of rules for assigning an order of decreasing priority (a± d) to 
each of the substituents attached to the asymmetric carbon, decreasing atomic number 
being the simplest situation. The molecule is then viewed with the lowest priority group 
away from the viewer. If the direction of rotation from the highest to the lowest priority 
group is to the left, the enantiomer can be described as S (sinister) and, if the direction 
of rotation is to the right, then the molecule is R (rectus) (Landoni et al., 1997; Landoni 
and Lees, 1996). 
2.1.6 Examples from the pharmacology 
Many drugs currently used in medical practice are mixtures of enantiomers. Often the 
two enantiomers differ in their pharmacokinetic and pharmacodynamic properties. 
Replacing existing racemates with single isomers has resulted in improved safety and/or 
efficacy profile of various racemates. Some important chiral switches that have yielded 
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safer alternatives include levosalbutamol, S (+) ketamine, S (+) zopiclone, levocetirizine, 
S (+) amlodipine, S (+) metoprolol, S (+) omeprazole, S (+) pantoprazole and R (-) 
ondansetron (Patil and Kothekar, 2006).  
 
2.2 The dissociative anaesthetics drugs 
Dissociative anaesthetic drugs are cyclohexanone derivates (Fig. 6) that induce 
anaesthesia, analgesia, and immobilisation in the treated animal. The term ‘dissociative’ 
represents the state of the immobilisation induced by cyclohexamines. In this condition, 
the treated animal is typically unresponsive to stimulation but retains normal pharyngeal 
and laryngeal reflexes (cataleptic stage). The eyes remain open and may show 
nystagmic gaze. Palpebral and corneal reflexes are often present. This class of 
anaesthetics does not produce muscle relaxation. On the contrary, they may induce 
muscle rigidity or twitching. Dissociative anaesthetics induce analgesia, disorientation, 
excessive salivation, hypertension or hypotension, hallucinations, vocalisation, and may 
develop tonic clonic convulsions (Nielsen, 1999). 
 
Fig. 6: Cyclohexanone derivate 
 
Cyclohexanone derivates anaesthetics include: phencyclidine, tiletamine and ketamine. 
2.2.1 Phencyclidine (PCP) 
PCP (Fig. 7) was the first cyclohexanone derivative to be used for animal immobilisation. 
Originally labelled as CI-395, it was synthesised for use in human anaesthesia in the early 
1960s. Because of illicit human use (strong hallucinogenic action) the molecule was 
abandoned for this purpose, reclassified by the Food and Drug Administration and taken off 
the market in 1978 (Vollenweider, 2003 and Vollenweider-Scherpenhuyzen, 2003; Nielsen, 
1999). 
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Fig. 7: Phencyclidine (PCP) 
2.2.2 Tiletamine (HCl) 
Available only in combination with the benzodiazepine, zolazepam, in the commercial 
form known as Telazol ® and Zoletil ®, Tiletamine (Fig. 8) was synthesised in the 1970s 
as CI-634. The factors that limit, under practice conditions the use of this combination 
are the instability of zolazepam once mixed with tiletamine (Nielsen, 1999) and 
furthermore, the elevated price, compared to racemic ketamine. It is commonly used, 
however, for wildlife or field anaesthesia (Cohen and Brae, 1978). 
 
Fig. 8: Tiletamine (HCl) 
 
 
2.3 Ketamine 
2.3.1 History 
Ketamine hydrochloride was first synthesised in the 1962 in the Parke Davis Lab (today 
a part of the pharmaceutical company Pfizer) by C. Stevens and was originally named 
CI-581 (CI state for Clinical Investigation). Stevens was in search for a safer alternative 
to PCP. Ketamine was first patented in 1963 under a Belgian and years later (1966) 
under US patent as an anaesthetic for humans and animals. In 1970, ketamine was 
approved by the Food and Drugs Administration and ketamine became commercially 
available as Ketalar ®.   
Ketamine was originally used as an anaesthetic in the Vietnam War to anaesthetise 
American soldiers (Mellor, 2005). This experience suggested that ketamine could be 
useful in civilian contexts to provide anaesthesia or immobilisation for outdoor life-saving 
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emergency surgeries or in mass casualties where rapid procedures were required 
(Bonanno, 2002).  
Ketamine is a very versatile and inexpensive drug. In regions where access and funding 
(as in the developing world) for a wider range of drugs is problematic, its broad range of 
clinical applications is ideal. Furthermore, its favourable safety profile and ease of 
storage makes it ideal for use in areas where refrigerators, complex monitoring, 
electricity and oxygen may all be scarce or unreliable (Craven, 2007). 
The first veterinary use is already described in 1972 for chemical restrain of nonhuman 
primates (Bree et al., 1972). 
2.3.2 Chemistry: Isomerism of ketamine  
Ketamine is a keto-amine, so named as it has a ketone C=O group bonded to carbons 
either side, as well as an amine group. As such it resembles NMDA (Fig. 9 and 10) 
 
 
Fig. 9: Ketamine Fig. 10: NMDA 
 
 
Ketamine contains a chiral centre at the C-2 carbon of the cyclohexanone ring, so that 
two enantiomers exist S (+) ketamine and R (-) ketamine (Fig. 11). 
 
R (-) ketamine S (+) ketamine 
Fig. 11: Two isomers of ketamine 
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2.3.3 Pharmacokinetics 
The use of ketamine, administrated by infusion or injection, in the proximity to the spinal 
cords, i.e. Intrathecally, into the CSF or epidural into the fatty tissue surrounding the 
dura (also known as neuroaxial drug administration techniques) is in various stages of 
investigation (Schug et al., 2006). 
Thanks to its good lipid solubility, ketamine crosses the brain-blood barrier quickly and 
in short time (less than one minute) its action in CNS starts (Cohen et al., 1973). 
Racemic ketamine has relatively short distribution and elimination half-lives: the alfa-
elimination phase last only a few minutes, and the beta-elimination half-life is 2-3 hours 
(Kohrs and Durieux, 1998).  
The compound is metabolised by hepatic cytochrome p450 system, where it is bio 
transformed by N-demethylation to norketamine (metabolite 1), which retains the 
pharmacological activity and then undergoes oxidation of the cyclohexanone ring to 
form dehydronorketamine (metabolite 2) (Bolze and Boulieu, 1998; Seay et al., 1993). 
Its primary metabolite norketamine is only 1/3 to 1/5 as potent as the original compound 
but might be involved in the prolonged analgesic actions of ketamine. The metabolites 
are excreted by the kidney (Roncada et al., 2003; Kohrs and Durieux, 1998). 
Humans. A variety of pharmacokinetic studies on ketamine using 2 or 3 compartments 
models are available (Hijazi et al., 2003). 
Animals. The comparison of the pharmacokinetics of ketamine HCl in cats, dosed at 25 
mg/kg, after IV and IM, and rectal administration, showed rapid absorption with all three 
ways of administration (Hanna et al., 1988). The rectal administration of Ketamine HCl 
showed a minimal influence of the first–pass effect and a statically similar elimination 
rate (beta) in rats (White and Holmes, 1976), dogs (Schwieger et al., 1991), and horses 
(Muir and Sams, 1992; Waterman et al., 1987). 
Ketamine can be applied PO (Grant et al., 1984), IM, SQ, IV, intra nasal (Axiak et al., 
2007), rectally (Kruger, 1998 and Hanna et al., 1988), but tissue irritation may occur 
after IM injection site (Booth, 1988). 
 
 
 
2.3.4 Pharmacodynamics 
2.3.4.1 Action of ketamine 
In the brain, ketamine acts on receptors located in the thalami-neocortical projection 
system, where it depresses neuronal function of the neocorticothalamic axis and the 
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central nucleus of the thalamus, while it stimulates parts of the limbic system, including 
hippocampus. The result is dissociation between these brain areas (Miyasaka and 
Domino, 1968).  
Hallucinatory behaviour, which may progress to delirium, may occur during emergence 
from anaesthesia. Ketamine-induced depression of the inferior colliculus and medial 
geniculate nucleus leading to misperception of auditory and visual stimuli may be 
responsible for this reaction (White, 1982).  
In dogs ketamine, when used alone, induces extreme muscle tone, exuberant 
spontaneous movement, violent recovery, and occasional convulsions. In "high-strung" 
small breed dogs, small ketamine doses produce insufficient anaesthesia and have 
greater tendency to cause seizures. Excessive salivation may occur during ketamine 
anaesthesia, but this can be controlled with atropine (Navarro and Friedman, 1975). 
2.3.4.2 Receptors of ketamine 
At a molecular level, ketamine binds to various receptors: 
- NMDA-Glutamate receptors 
- Nicotine cholinergic receptors  
- Monoaminoergic receptors 
- Opioids receptors 
- Muscarin cholinergic receptors 
- Voltage-dependent ion channels such as Na and L-Type Ca Ions 
channel 
2.3.4.2.1 NMDA glutamate receptors 
N-Methyl-D-aspartate (NMDA) receptors are members of the glutamate receptors 
channel super family, which mediate most of the fast excitatory synaptic transmissions 
in the central nervous system.  
The NMDA receptor is highly permeable to calcium and sodium ions and plays a key 
role in the plasticity of synapses, which is believed to underlay memory and learning, as 
well as the development of the nervous system. 
This receptor opens in response to binding of the neurotransmitter glutamate. Besides 
the glutamate (NMDA) binding site, there are also multiple binding sites on the NMDA 
receptor for glycine and polyamines. NMDA receptors possess 4 trans membrane 
helical domains (Fig. 12) and can be blocked by magnesium ions, inhibited by zinc ions, 
and modulated by arachidonic acid. 
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Fig. 12: Scheme of a NMDA Receptor which mediates most of the fast excitatory synaptic 
transmissions in the central nervous system 
 
At the spinal cord level, NMDA receptor activation triggers a cascade of events leading 
to sensitisation of dorsal horn wide dynamic range neurons. There is a significant 
increase in intracellular calcium and activation of protein kinases and phosphorylating 
enzymes. NMDA receptor stimulation will also increase the production of spinal 
phospholipase and induce the production of nitric oxide synthetase. The prostaglandins 
and nitric oxide, which are subsequently produced and released into the extra cellular 
milieu, can facilitate further release of excitatory amino acids and neuropeptides from 
primary afferent pain fibres. 
Ketamine inhibits the NMDA receptor by binding in a non-competitive manner to its PCP 
site. The blockade is time, concentration, and stimulation frequency dependent (use 
dependent) (MacDonald et al., 1987). 
2.3.4.2.2 Opioid receptors 
It is generally believed that NMDA receptor antagonism accounts for most of ketamine 
anaesthetic and analgesic effects, where as ketamine agonistic effects at opioid 
receptors within the central nervous system seem to play a minor role in its anaesthetic 
or analgesic effect (Hustveit et al., 1995).  
The psychomimetic side effect of ketamine may be explained by the interaction with     
ĸ-opioid receptors, because ĸ-agonist produces similar effect. Its low affinity for these 
receptors compare to NMDA receptors suggest that the interaction is not of major 
clinical importance (Kohrs and Durieux, 1998).  
Few studies have assessed the involvement and contribution of the Π-opioid receptor in 
generating ketamine respiratory effects (Latasch and Freye, 1993). Opioid receptors 
and their endogenous ligands are found in large concentrations in areas of the CNS 
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involved in the control of breathing. Administration of ketamine results in respiratory 
depression, probably because of its interaction with Π–opioid receptors (Sarton et al., 
2001). 
2.3.4.2.3 Cholinergic and adrenergic signalling: nicotine- and muscarin- 
cholinergic receptors 
Both receptors (nicotine- and muscarin- cholinergic receptors) are affected by ketamine 
(Kress, 1994). 
The effect of ketamine on human nicotinic cholinergic receptors is inhibition depending 
on type of subunit receptors (Yamakura et al., 2000).  
The postsynaptic inhibitory effect of ketamine on nicotinic acetylcholine receptors in 
skeletal muscle is not necessarily noticeable clinically, as ketamine increases muscle 
tone by central mechanisms. Muscarinic receptors are also inhibited (Durieux, 1995).    
S (+) ketamine shows a twofold greater affinity with the muscarinic receptor than does  
R (-) ketamine (Hustveit et al., 1995). However, overall affinity for the muscarinic 
receptor is ten to twenty folds less than NMDA receptor binding (Aronstam et al., 1982). 
Emergence side effects may be partly related to inhibition of cholinergic transmission 
(Durieux, 1995). 
Ketamine profoundly inhibits muscarinic signalling. This effect might explain some of the 
anti cholinergic clinical effects of ketamine, both: central (effects on memory and 
consciousness) and peripheral (prominent sympathetic tone, bronchodilatation, 
mydriasis) as stated by Durieux (1995). 
2.3.4.2.4 GABA receptors  
GABA is the most common inhibitory neurotransmitter in the CNS, and GABA signalling 
neurones account for approximately 30% of all synaptic connections in the CNS (Kohrs 
and Durieux, 1998). 
Although the effect of ketamine as GABA signalling seems established (Lin et al., 1992), 
the concentrations used in the study were higher than those used normally in the clinic. 
Based on current knowledge, this interaction seems to be of minor importance for 
clinical practice (Kress, 1994). 
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2.3.4.3 Effect on different organ system 
2.3.4.3.1 Effect on the central nervous system 
Ketamine produces a dose related unconsciousness and analgesia (Cohen et al., 1973).  
Cerebral blood flow (CRF) and Intracranial pressure (ICP). Cerebral blood flow 
(CBF): ketamine racemic form and S (+) form, produced similar EEG changes (Thiel et 
al., 1992). 
Hallucinations during recovery. The ketamine induced depression of the inferior 
colliculus and medial geniculate nucleus leading to misperception of auditory and visual 
stimuli may be responsible for this reaction. In cats emergence reactions are 
characterised by ataxia, increased motor activity, hyperreflexia, sensitivity to touch, 
avoidance behaviour of an invisible object (‘watching butterflies’) and sometimes violent 
recovery (Wright, 1982). The combination of ketamine with alpha-2-agonists, 
acepromazine or a benzodiazepine derivate, decrease the incidence of adverse 
emergence reaction (Lin et al., 1992). At low doses, stimulant effects predominate and 
the effect on environmental conditions is significant; with higher doses, psychedelic 
effects predominate and the effect of the environment diminishes (Wolff and Winstock, 
2006). 
Ketamine is not approved in the Unites States for patients less than 16 years of age. 
Ketamine induces neuronal injury and/or death in the brains of juvenile rodents 
(Ikonomidou et al., 1999 and 2001; Jevtovic-Todorovic et al., 2000). In a review study of 
environmental agents (like ethanol, PCP, ketamine, benzodiazepine, halothane, 
isoflurane, and propofol) that have the potential to trigger apoptosis of neurones in 
developing brain, the authors invite to further research. During the synaptogenesis 
period (from the last trimester of pregnancy and several years after birth in humans) the 
transient interference in the activity of GABA and NMDA receptors causes 
neurodegenerative cell death (Wang and Slikker, 2008 and Olney et al., 2000). Scallet 
et al. (2004) confirmed that ketamine has been shown to induce neuronal death in rats 
during early development. The effects of ketamine are dose dependent; data suggest 
that limiting exposure limit the potential for neurodegeneration. In animal models the 
doses and durations of ketamine exposure that resulted in neurodegeneration were 
slightly larger than those used in the clinical setting, but there are insufficient data to 
either support or refute the clinical applicability (Mellon et al., 2007). Most of the recent 
preview studies, have the goal to warn clinicians of use of ketamine because of its 
neurotoxicity (Lois and De Kock, 2008; Vutskits et al., 2007;). 
Ketamine has been shown to have neurotoxic properties, when administered 
neuraxially, at millimolar concentrations ketamine induces apoptosis via the 
mitochondrial pathway, independent of death receptor signalling. At higher 
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concentrations necrosis is the predominant mechanism. Less toxicity of S (+) ketamine 
was observed in neuroblastoma cells, but this difference was minor and therefore 
unlikely to be mediated via the NMDA receptor (Braun et al., 2010). 
Ketamine use in children’s anaesthesia indicates interesting properties such as the 
prevention of surgery and opiate induced hyperalgesia and the anti-proinfiammatory 
characteristic (by promoting the self limitation of the inflammatory response that follows 
surgery). This positive effects of ketamine are contrasted by other more potentially 
deleterious effects proven by experiments on rats treated with ketamine at anaesthetic 
doses during the critical period for the central nervous system development, where long-
term behavioural deficits were noted (Lois and De Kock, 2008).  
2.3.4.3.2 Effects on cardiovascular system 
Indirect cardiovascular stimulation. Following ketamine heart rate and arterial blood 
pressure increase as a result of direct CNS stimulation. Plasma concentration of 
epinephrine and norepinephrine increase within 2 min after IV administration of 
ketamine. As a consequence heart rate, cardiac output and arterial blood pressure 
increase following administration (Brake et al., 1973). 
In a study reporting cardiovascular response after intracisternal injection of ketamine or 
saline vehicle, a dose dependent increase in blood pressure and heart rate was 
observed (0.5 or 1.0 mg). In contrast, higher dose of ketamine (4 mg) produced a fall in 
blood pressure and heart rate (Seth et al., 1990). 
Inotropic action on myocardium. The inotropic effect is controversial. Some studies 
(in vivo and in vitro) support the thesis of positive inotropic effect (Cook et al., 1991; 
Riou et al., 1990; Riou et al., 1989; Tweed et al., 1972). Others, however, support the 
negative inotropic effect (Kongsayreepong et al., 1993; Rusy et al., 1990; Goldberg et 
al., 1970; Dowdy and Kaya, 1968). In anaesthetic doses, ketamine may inhibit 
catecholamine beta-adrenergic activity, negating a direct depressant effect upon the 
heart (Reyes Toso et al., 1992). 
Ketamine is used in patients suffering from hemodynamic shock, active asthmatic 
disease, and anaesthesia in children and intensive care settings (Kohrs and Durieux, 
1998). 
2.3.4.3.3 Effects on respiratory system  
Respiration pattern. Ketamine provokes only mild respiratory depression (Werner et 
al., 1997). Ketamine is one of the most reliable anaesthetic agents for anaesthesia 
induction and maintenance, since at clinically useful dose rates, it does not impair 
airway maintenance and spontaneous respiration (Paix et al., 2005). The transient 
apnoea induced by ketamine appears to be dose dependent. At higher doses, 
respiration is characterised by an apneustic, shallow, and irregular pattern (Sears, 
20 
1971). Severe depression or arrest with over dosage has been described in humans 
and cats (Bree et al., 1972; Child et al., 1972; Kopman, 1972). 
Secretion from salivary glands and respiratory tract mucus. Ketamine can cause 
increased salivation and secretion of respiratory track mucus, which can easily be 
controlled by administration of an anti-cholinergic (Wright, 1982).  
Reflexes. Laryngeal and pharyngeal reflexes are well maintained during ketamine 
anaesthesia. Nevertheless, most species can be intubated when anaesthetised with 
ketamine in combination with other anaesthetic agents or sedatives (Wright, 1982). 
Pulmonary capillary effect. An analysis of ketamine responses in the pulmonary 
vascular bed of the cat showed that ketamine had a significant vasodilator activity in the 
pulmonary vascular bed (Kaye et al., 2000). 
2.3.4.3.4 Inhibition of inflammatory response 
There are promising effects of ketamine on the inflammatory response in vitro and in 
vivo. Intravenous anaesthetics generally depress the endotoxin-induced pro-
inflammatory cytokine activity and its consequent nitric oxide generation, free radicals 
production and neutrophil activity. Different intravenous anaesthetics, such as propofol, 
ketamine, benzodiazepine and barbiturates, which produce different levels of inhibition 
of inflammatory effects, may be of great relevance to the practice of intensive care, and 
intravenous anaesthetics may play significant roles in this regard (Lois and De Kock, 
2008; Tsao et al., 2005). 
2.3.4.3.5 Analgesia 
Many mechanisms are at the origin of ketamine analgesic property: 
- Blockade of the spinoreticular tract (Sparks et al., 1973). 
- Depression of nuclei of the medial medullary reticular formation in the cat 
(Ohtani et al., 1979). 
- Suppression of lamina of the spinal cord (Kitahata et al., 1973);  
- Interaction with CNS and spinal cord opiate receptors (Hanaoka et al., 
1990; Smith et al., 1990; Finck and Ngai, 1982). 
- NMDA receptors antagonism.  
The degree of analgesia appears to be greater for somatic pain than for visceral pain 
(Haskins et al., 1975 and Sawyer et al., 1991 ). In the cat analgesic effect of ketamine 
(at a dose of 4 mg/kg IV) in visceral pain is similar to the effect covered by butorphanol 
(at a dose of 0.1 mg/kg IV), (Sawyer et al., 1990). Ketamine has analgesic 
characteristics even at sub anaesthetic dosages (Clements and Nimmo, 1981). 
Recently, the use of ketamine in form of chronic administration for analgesia was 
investigated (Ben-Ari et al., 2007). The primary role of ketamine in such low doses 
21 
consists in 'anti-hyperalgesia', 'anti-allodynia' or 'tolerance-protection'. Therefore, 
ketamine plays a role in the treatment of opioid resistant or 'pathological' pain (central 
sensitisation with hyperalgesia or allodynia, opioid induced hyperalgesia, neuropathic 
pain) rather than as an 'analgesic' in its own right. Low dose ketamine also has 
'preventive analgesia' properties (Visser and Schug, 2006) as it prevents central 
sensitisation. Furthermore, in higher doses it provides effective and safe sedation and 
analgesia for painful procedures (Visser and Schug, 2006).  
Acute pain management. Pyati and Gan (2007) reviewed the evidence on the opioid-
sparing effect of ketamine and other analgesic drugs in the peri-operative pain 
management. According to the authors, most available data support the addition of 
these molecules to routine analgesic techniques to reduce the need for opioids and 
improve the quality of analgesia by their synergistic effect. 
Chronic pain management. NMDA agonists such as ketamine are well known to 
attenuate central sensitisation and palliate neuropathic pain (Okon, 2007). 
Ketamine has been successfully used in patients with advanced cancer that resisted to 
ordinary pain therapies. Ketamine was infused at slow rate from over 6 hours to 48 days 
and only few patients showed disorientation and drowsiness during infusion, but no 
cardiovascular or respiratory complication (Kanamaru et al., 1990). In a recent review, 
ketamine counts to the various analgesics in use to control cancer pain (Bell, 2009; 
Newsome et al., 2008). 
 
2.3.5 Club drugs: Recreational use of ketamine 
Club drugs are substances commonly used at nightclubs, music festivals, raves, and 
dance parties to enhance social intimacy and sensory stimulation. The most widely used 
club drugs are 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy; 
gamma-hydroxybutyrate (GHB); flunitrazepam (Rohypnol ®); and ketamine (Ketalar ®). 
These drugs are popular because of their low cost and convenient distribution as small 
pills, powders, or liquids. Club drugs usually are taken orally and may be taken in 
combination with alcohol, or with other drugs (Gahlinger, 2004). 
The incidence of recreational ketamine use increased through the end of the 20th 
century, especially in the context of raves and other parties. Production for recreational 
use has been traced to 1967, when it was referred to as "mean green" and "rockmesc". 
Recreational names for ketamine include "K", "Ket", "Special K", "Vitamin K" and "King 
Kev". 
At low doses, stimulant effects predominate and the effect of environmental conditions is 
significant; with higher doses, psychedelic effects predominate and the effect of the 
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environment diminishes. The potential of ketamine as a novel clinical and research tools 
matched by its abuse potential outside medical settings (Wolff and Winstock, 2006).  
 
 
 
2.4 S (+) ketamine 
2.4.1 History 
For many years, racemic ketamine has been used widely in human and veterinary 
medicine, but collateral effects have been described for the racemate, like 
cardiovascular stimulation and hallucinations (White, 1982).  
2.4.2 Use in animals and humans  
S (+) ketamine is used for premedication, sedation, induction and maintenance of 
general anaesthesia, which is than termed "dissociative anaesthesia". S (+) ketamine is 
an ideal anaesthetic agent for trauma victims, patients with hypovolemic and septic 
shock and patients with pulmonary diseases. Even sub anaesthetic doses of this drug 
have analgesic effects, so ketamine is also recommended for post-operative analgesia 
and sedation (Sinner and Graf, 2008).  
S (+) ketamine at half-dose of racemic ketamine is as potent as racemic ketamine in sub 
anaesthetics doses with powerful analgesics properties. S (+) ketamine exerts less 
adverse effects on measurable cerebral function and induces a significantly smaller 
increase in heart rate. Since states of impaired consciousness and disorientation are 
especially disturbing under emergency conditions, the use of S (+) ketamine as a potent 
analgesic for therapeutic use in emergency and disaster medicine deserves further 
investigation (Pfenninger et al., 1994).  
In humans S (+) ketamine widens the anaesthesiologist's possibilities of premedication 
considerably. Induction of anaesthesia with stabilised spontaneous ventilation becomes 
in fact possible in children with difficult condition for venous puncturing, in very anxious 
children, and in those who are not able to accept the necessity of a treatment (Kruger, 
1998). 
S (+) ketamine binds approximately two to fourfold stronger to opioid receptors than 
does R (-) ketamine, still the affinity of ketamine for these receptors is 10 (μ) to 20 (k) 
times less than for NMDA channel. This suggests that this interaction is not of clinical 
importance (Hustveit et al., 1995). 
Veterinary medicine. The 18th of Mai 2006 Swissmedic gave the authorisation for the use 
and trade of S (+) ketamine in cats. The pharmaceutical company Dr. E. Graeub AG 
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became the first company to register the S (+) ketamine is under the trade name Keta S ®, 
ad us vet.  
Cats. A lower dose of S (+) ketamine was necessary compared to racemic ketamine for 
elective ovarioectomy (Eichenberger et al., 2005).  
S (+) ketamine has been successfully used in ASA III cat patients offering significantly 
faster recovery period than the racemic mixture. Post-operative analgesia and 
emergence quality were also judged significantly better (Baumgartner et al., 2002).  
In male cats undergoing routine neutering surgery, anaesthesia with S (+) ketamine, at a 
60% the dose of racemic ketamine, provide faster recovery, increased post operative 
respiratory rates, and adequate post operative analgesia (Larenza et al., 2008). 
Horses. In study comparing the effect of plasma concentrations obtained by a low dose 
constant rate infusion (CRI) of racemic ketamine or S (+) ketamine on the nociceptive 
withdrawal reflex (NWR) in standing ponies, the NWR was significantly depressed in the 
racemic ketamine group at plasma concentrations between 20 and 25 ng/mL of each 
enantiomer. No significant NWR depression in the S (+) ketamine group could be 
observed. The antinociceptive activity in standing ponies, demonstrated as a depression 
of the NWR, could only be detected after treatment with racemic ketamine. S (+) 
ketamine may have lacked this effect as a result of lower plasma concentrations, a more 
rapid metabolism or a lower potency of S (+) ketamine in horses (Peterbauer et al., 
2008).  
The plasma concentrations of ketamine and norketamine enantiomers were determined 
by capillary electrophoresis. The residence times were lower for S (+) ketamine after S 
(+) ketamine administration compared to racemic ketamine. The time to standing 
position (TSP) during recovery was significantly shorter after S (+) ketamine 
administration compared to racemic ketamine (Larenza et al., 2008) at equipotent 
doses. 
In an evaluation of the pharmacokinetics of ketamine and norketamine enantiomers, 
Larenza et al. (2007), found that the plasma concentrations of S (+) ketamine decreased 
and biodegradation products increased more rapidly after S (+) ketamine CRI as 
compared with racemic ketamine CRI, indicating that S-enantiomer was eliminated 
faster when infused alone instead of as part of a racemic mixture. Furthermore, the 
recovery from anaesthesia was better with S (+) ketamine infusions as compared with 
racemic ketamine (Larenza et al., 2009 and 2008). Another study in Shetland Ponies 
confirmed these results showing a faster recovery after administration of S (+) ketamine 
as compared with its racemic mixture (Larenza et al., 2009 and  2007). 
Theurillat et al., (2005), describe a method for the simultaneous determination of the 
enantiomers of ketamine and norketamine in equine plasma. The ketamine N-
demethylation was demonstrated to be enantioselective and the concentrations of the 
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two ketamines enantiomers in plasma were equal, whereas S (+) norketamine was 
found in a larger amount than R (-) norketamine. 
Pig. A bolus injection of S (+) ketamine was associated with less cerebral and systemic 
hemodynamic depression than racemic or R (-) ketamine in equipotent doses an 
experimental model. These findings indicate possible advantages of S-ketamine over 
racemic ketamine (Schmidt et al., 2005). 
Dogs. The application in dogs of a smaller dose of S (+) ketamine will produce a shorter 
time to sternal recumbency and a shorter time of recovery from anaesthesia when 
compared to racemic ketamine (Duque et al., 2008).  
In dogs the use of S (+) ketamine anaesthesia resulted in the shorter duration of 
unconsciousness, shortest time to sternal recumbency (TSR) and more quiet recovery 
from anaesthesia when compared to racemic ketamine (Muir and Hubbell, 1988). The 
application of a smaller dose of S (+) ketamine, in comparison with racemic ketamine, 
produced a faster recovery from anaesthesia with a minor incidence of psychomimetic 
side effects, at similar cardiovascular effects during anaesthesia (Oleskovicz et al., 
2009; de Almeida et al., 2005; Duque et al., 2004). The R (-) enantiomer is a more 
potent bronchodilator than the S (+) ketamine during ACh-mediated ASM contraction. 
This effect appears to be caused by differential actions on receptor-operated calcium 
Channels (Pabelick et al., 1997). 
The potency ratio between racemic ketamine and S (+) ketamine in dogs is smaller than 
reported in other species. A dose reduction of 50% of S (+) ketamine in comparison to 
racemic ketamine, as usually performed in humans, does not result in equipotent 
anaesthetic effects in dogs (Duque et al., 2004). 
2.4.3 Effects on different organ system 
CNS effects. Racemic ketamine and S (+) ketamine produce similar EEG changes in 
the first phase of after injection. However, 120 min after injection the EEG shows more 
activity following racemic ketamine as compared with S (+) ketamine. Although, a 
statistically significant difference could not be confirmed, a better recovery of cortical 
function after S (+) ketamine administration is probable (Thiel et al., 1992).  
Cardiovascular effects. Ketamine and its isomers were found to act as cardiac 
depressants by affecting calcium homeostasis in isolated ferret and frog ventricular 
myocardium (Kongsayreepong et al., 1993). However, as Graf et al. (1995) have 
reported using the isolated perfused heart model, S (+) ketamine is less depressant 
compared to racemic and isomeric R (-) ketamine. A later study of Kunst et al. (1999) on 
human myocardium concluded that S (+) ketamine at lower doses (73 microM) 
increased isometric force, isotonic shortening, contractility, and relaxation. At higher 
doses (730 microM) a direct inotropic action was observed after perfusion with ketamine 
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and isomers, which was accompanied by decreased intracellular Ca2+ transient (Kunst 
et al., 1999). 
Pain. S (+) ketamine is approximately twice as potent as the racemic mixture in 
inhibiting central summation of pain (Arendt-Nielsen et al., 1996). In this way, the S (+) 
isomer offers advantages in the clinical use by using equipotent doses causing less 
collateral effects than the racemic ketamine. S (+) ketamine has an opioid-sparing effect 
after cardiac surgery. The analgesic property of S (+) ketamine was also supported by 
the finding that the time to the first request for an analgesic after surgery was longer in 
the ketamine group (Lahtinen et al., 2004). S (+) ketamine at half dose of racemic 
ketamine is as potent as racemic ketamine in sub anaesthetic doses with powerful 
analgesic properties (Pfenninger et al., 1994). 
Recovery. White et al. (1985) showed that patients felt more comfortable after S (+) 
ketamine anaesthesia compared with the racemic mixture, mainly because of decreased 
agitation, disorientation, and anxiety. The effect on vigilance was less impaired by S (+) 
ketamine, psychological assessment showed a prompter recovery of visual 
attentiveness and sensimotor performance in the S (+) ketamine group, and subjective 
mood was judged by volunteers to be significantly better after S (+) ketamine (Doenicke 
et al., 1992). The additional administration of a benzodiazepine provided both drugs with 
a significantly higher rate of acceptance, but also an increased duration of recovery 
(Kohrs and Durieux, 1998). Taken together, these data suggest that S (+) ketamine 
allows for the reduction of the anaesthetic doses, with a resultant faster recovery and 
(possibly) some diminution in side effects (Kohrs and Durieux, 1998). 
 
 
2.5 Anaesthetic consideration for elective orchiectomy in dogs 
General anaesthesia is mandatory for elective surgeries involving the reproductive tract 
under the application of local anaesthesia. Numerous general anaesthesia protocols 
may be used for elective surgery in healthy animals (ASA I and II). 
2.5.1 Dissociative anaesthesia using diazepam or xylazine and ketamine 
- Diazepam (Vallium ®) 0.05-0.25 mg/kg IV has sedative, anti-convulsive, 
anti-arrhythmic and muscle relaxation properties. At high doses it produces 
hypnosis ad ataxia. 
- Xylazine (Rompun ®) 0.5-2 mg/kg IM produces sleep-like symptoms, good 
analgesia and good muscle relaxation.  
- Ketamine (Ketanest ®; Ketalar ®) 10-30 mg/kg IM gives analgesia and 
anaesthesia  
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During 1993, 66 small animal practices of Ontario, participated in a prospective study to 
evaluate the incidence and details of anaesthetic-related morbidity and mortality (Dyson 
et al., 1998). Considering a total of 8,087 dogs, the incidences of complications were 
2.1% and death occurred in 0.11% of cases. Significant complications in dogs were 
associated with xylazine, heart rate monitoring, ASA 3 or more patients. Cardiac arrest 
in dogs was associated with xylazine use, while the use of ketamine was associated 
with high safety (Dyson et al., 1998). 
2.5.2 Dissociative anaesthesia using tiletamine and zolazepam  
Powder mixture contains 250 mg of tiletamine and 250 mg of zolazepam (Telazol ®) in 5 
ml solution. Telazol is expensive and once mixed it can’t be stored for a long time. 
The dose can vary from 7 to 25 mg/kg BM by IM administration and from 5 to 10 mg/kg 
by IV administration respectively, depending on anaesthesia indication and purpose 
(immobilisation to small surgery procedure). Those combinations fail to induce a surgical 
level of anaesthesia (Hellebrekers et al., 1998). 
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2.5.3 Dissociative anaesthesia using medetomidine, butorphanol and ketamine  
- In Switzerland, since 2007, the pharmaceutical company Dr. E. Graeub 
Veterinary products, provides the veterinary clinician with a practical table 
(Table 1) that help the routine use of the combination of butorphanol 
(Morphasol ®), Medetomidine (Dorbene®), and racemic ketamine 
(Ketasol®). 
- Table 1: Protocol for combination of  Morphasol ® - Dorbene® - Ketasol® 
 
- Medetomidine (Domitor ®, Dorbene ®) 450 ?g/m2 BSA (body surface 
area), used intramuscularly (IM) 
- Butorphanol (Morphasol ®, Dolorex ®, Alvegesic 1% forte ®) dose 0.2 mg/kg 
BW, used intramuscularly (IM) 
- Racemic ketamine (Ketasol®, Narketan ® 10) Racemic Ketamine 4 mg/kg 
BW intravenously (IV) 
A study in dogs (Ko et al. 2000), suggested that the combination of medetomidine with 
butorphanol or ketamine resulted in more reliable and uniform sedation in dogs as 
compared with medetomidine alone.  
In a study of Girard et al. (2010) the sedative effects of low-dose medetomidine, 
butorphanol, and their combination were tested in dogs. The combination of low-dose 
medetomidine (1 ?g/kg IV) and butorphanol (0.1 mg/kg IV) produced a stronger 
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sedation than medetomidine or butorphanol alone. Heart rate was significantly 
decreased in both medetomidine groups (Girard et al., 2010). 
2.5.4 Anaesthesia using propofol   
Propofol in Switzerland is sold under the trade name Disoprivan®, and it is registered for 
the human medicine use.  
Propofol can be used in dogs in the dosage of 4-8 mg/kg IV, this dose must be reduced 
to 4-5 mg/kg after acepromazine, and to 1-2 mg/kg after medetomidine premedication, 
respectively. Propofol can be use for anaesthesia induction and for anaesthesia 
maintenance (Glowaski et al., 1999; Pascoe, 1992).  
In a study of Hellebrekers et al. (1998), the clinical efficacy and safety of propofol and of 
racemic ketamine was compared. A higher rate of adverse side effects related to the 
use of racemic ketamine was reported.  
 
2.6 Potential economical / research impact 
In 1992, the Food and Drug administration stated that separation of stereoisomers did 
not receive appropriate attention in commercial drug development and that, despite 
technical difficulties and high cost, this issue could open new horizons in therapeutics 
(Kohrs and Durieux, 1998). 
About 56% of the drugs currently in use are chiral compounds, and 88% of these chiral 
synthetic drugs are used therapeutically as racemate. If the qualitative and quantitative 
pharmacokinetic and pharmacodynamic effects are similar, the enantiomers do not need 
to be separated. However, if different enzymes handle the metabolism of the different 
stereoisomers, and if their pharmacodynamic effects have differences either in strength 
or in quality, enantiospecific analysis is urgently needed. Therefore, there is a great 
need for studies focussing on these differences to improve therapeutic applications of 
chiral drugs (Rentsch, 2002). This may results in higher therapeutic and cost 
effectiveness. 
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3. Methods  
3.1 Study design 
3.1.1 Overall design 
The experimental study was designed as a randomised blinded prospective clinical trial 
according the VICH guidelines on Good Clinical Practice (GCP) and approved by the 
Cantonal Veterinary Services of Canton Vaud. 
Two different types of ketamine (racemic ketamine: Ketasol-100 ad us. vet, and S (+) 
ketamine isomer: Keta-S ad us. vet were tested. Their intra-operative hemodynamic 
effects and ability to provide an adequate anaesthesia induction, maintenance and 
recovery were assessed in male dogs undergoing elective neutering. 
3.1.2 Treatment for control group 
As a treatment control, a ketamine racemate (Ketasol-100 ad us. vet) group was 
provided. However, the protocol for treatment did not differ for the control group. 
3.1.3 Randomisation method 
A total of 40 male dogs (client owned or belonging to the local animal shelter) classified 
as ASA I to II risk patients according to the American Society of Anaesthesiologist (ASA) 
were included in the trial. The randomisation was carried out by a supporting person (a 
veterinarian). The supporting person made use of the envelope system provided by the 
sponsor. This person also prepared the syringes of racemic ketamine or S (+) ketamine. 
3.1.4 Experimental units 
Two different groups (A and B) were formed, containing 20 animals each. One group 
was given S (+) ketamine and the other was given racemic ketamine. 
3.1.5 Blinding 
Blinding was ensured by the supporting person, who was responsible for keeping the 
blinding records and for preparing the test drugs.  The supporting person also handled 
the syringes to the investigator, ready to be used. The investigator remained unaware of 
the treatment identity during the entire animal phase. 
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3.2 Inclusion/exclusion criteria and removal after removal  
3.2.1 Pre-admission  
Careful physical examination was performed prior to the anaesthesia induction (See 
Annex A: Pre-admission examination). Dogs were classified according to the American 
Society of Anaesthesiologists’ (ASA) physical status classification in ASA risk groups I, 
II, III, IV and V. 
3.2.1.1 Inclusion criteria 
- ASA I-II 
- Non-sterilised male dogs 
3.2.1.2 Exclusion criteria 
- non-cooperative dogs 
- patients with pre-anaesthetic pathological disorders  
- cryptorchids 
Notice: ASA I or II means the dogs are suitable to receive general anaesthesia 
3.2.2 Removal after inclusion 
- Inability to induce anaesthesia with the pre-established drugs and doses  
- Inability to perform the pre-established surgery (surgical complications) 
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4. Procedures 
4.1 Key study dates 
The timeframe per case was approximately 3 hours, including clinical examination, 
anaesthesia pre-medication, animal preparation, anaesthesia induction, orchiectomy, 
monitoring and post-operative recovery and observation. After orchiectomy, all animals 
were observed and filmed during one hour. 
4.2 Animal selection and identification 
A total of 40 dogs entered the study. Animals were recruited from private clients of the 
veterinary practice, as well as from the local animal shelter (Société Vaudoise de la 
Protection des Animaux -SVPA-). The selection was based on a clinical pre-admission 
examination: anamnesis, physical exam (including: weight, hydratation status, 
temperature), cardiovascular and respiratory system (respiratory frequency, heart rate, 
mucous membrane colour, capillary refill time, pulse character, thoracic auscultation) 
and on specific inclusion/exclusion: risk classification of the American Society of 
Anaesthesiologists criteria (ASA, ASA I-II: low risk; ASA III: moderate risk, ASA IV-V: 
high risk). 
Each animal was identified (given name, owner’s surname, breed, age, sex); each dog 
received a serial study number, which was marked on its dossier as well as on the tape 
video document.  
At the end of each completed trial the patients’ dossier was stapled together to form a 
single file and stored safely by the investigator.  
4.3 Animal management and housing 
Private owners or SVPA provided all animals after having been informed on trial 
procedures and general anaesthesia risks and having signed the respective form 
(owner's consent, "Consentement du propriétaire"). The animals returned home on the 
same evening. The animals were kept in conventional kennels until anaesthesia 
induction and after completion of the visual examination (1 hour after surgery). A quiet 
environment at room temperature was granted during all clinical trials.  
4.4 Animal feeds 
Twelve hours before surgery, food was withheld to avoid the hazards of aspiration after 
anaesthesia induction. Free access to water was provided until one hour prior to the 
surgery and after complete recovery from anaesthesia. 
4.5 Investigational veterinary (IVP) and control products (CP) 
- IVP: S (+) ketamine 2 mg/kg BW intravenously (IV) (Keta-S ad us. vet., 
Injektionslösung Dr. E. Graeub AG, Bern, Switzerland) 
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- CP: racemic ketamine 4 mg/kg BW intravenously (IV) Ketasol-100 ad us. 
vet., Injektionslösung Dr. E. Graeub AG, Bern, Switzerland 
 
 
4.6 Treatments: Anaesthesia and surgery management 
4.6.1 Preparation and pre-medication 
The patients were admitted to the clinic the day of surgery. They were systematically 
examined to assess preoperative physiological parameters and ASA classification. Their 
inclusion or exclusion from the study was determined. Patients that met the inclusion 
criteria were then transferred to the preparation room next to the surgery room.  
The study animals in both groups were first filmed for assessment of normal behaviour 
in a foreign environment (preparation area) for a period of 5 minutes without collar and 
for 5 minutes with collar. Once ready each animal received an intramuscular (hind limb 
muscle) injection of 450 ?g/m2 body surface area (BSA) of medetomidine and 0.2 
mg/kg body weight (BW) butorphanol, mixed in the same syringe. Ten minutes after 
injection of sedative agents, the dogs were examined to assess the following 
parameters: respiratory frequency (RR), heart rate (HR), mucous membrane colour 
(MMC) and capillary refill time (CRT). 
When sedation was achieved, 20 - 30 minutes after medetomidine and butorphanol 
administration, an intravenous catheter was placed on the right or left cephalic vein.  
4.6.2 Anaesthesia induction 
After sedation, application of a venous catheter and preparation of the operative site 
(clipping of hairs, first alternated povidone-iodine and alcohol application), the dogs 
were moved by the investigator and the supporting person on a surgery table in lateral 
recumbency until ketamine (blind randomised) was administrated. 
Thirty minutes after administration of medetomidine and butorphanol, the dogs received 
2 mg per kg body weight of S (+) ketamine (s-ket group) or 4 mg/kg BW of racemic 
ketamine (rac-ket group). After anaesthesia was induced, the animals were intubated 
with a cuffed endotracheal tube after applying 2% lidocaine on each side of the larynx. A 
500 mL Ambu-bag was connected to the endotracheal tube via its one way valve and a 
constant oxygen flow (0,5-2 l/min, depending on the size of the dog) was insufflated 
through the distal port of its self inflating chamber during the whole surgery to ensure 
continuous oxygen delivery to the patient. Should apnoea have occurred, the dogs were 
ventilated using the Ambu-bag. The study animals were then placed in dorsal 
recumbency on the surgery table and prepared for surgery (a standard antiseptic 
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procedure was used). The scrotum was desensitised using 1 mg/kg BW of lidocaine 
prior surgical incision.  
Once the patient was positioned and the skin prepared, the investigator started the last 
phase of surgery preparation, including draping and preparation of the surgical 
instruments and material. Meanwhile, the supporting person (a veterinarian) applied the 
following anaesthesia monitoring instruments: 
- ECG, Pulsoxymeter (SpO2), arterial blood pressure (DAP, MAD, SAP): HP 
78352C, Hewlett Packard Corporation 
- Capnograph (EtCO2): Capnomac ™ II AGM-123, Datex Instrumentarium 
Corporation 
4.6.3 Anaesthesia maintenance and surgery 
Once ready, approximately 5 minutes after ketamine administration, surgery began 
(standard orchiectomy). Physiological parameters were monitored permanently during 
anaesthesia. Respiratory frequency, HR, oxygen saturation (SpO2), SAP, MAP, DAP, 
mucous membrane colour (MMC) and CRT were recorded every 5 minutes. 
Presence/absence of the eyelid reflex was evaluated by gently palpating the medial 
cantus of the eye. Should the patient have moved or displayed signs of awakening from 
anaesthesia (tachypnea, increased jaw tone, brisk eyelid reflex), an IV bolus of 1 mg/kg 
BW S (+) ketamine or 2 mg/kg BW was given for patients in the s-ket group or r-ket 
group, respectively. An infusion of 10 ml/kg/h of Ringer's lactated solution was delivered 
during the whole anaesthesia through the cephalic vein. 
Antibiotics (amoxicillin and clavulanic acid, Synulox ® Suspension Pfizer ad us. vet., 
Injektionssuspension 8.75 mg/kg BW, SC) and long term analgesics (carprofen,  
Rimadyl ® Pfizer ad us. vet., Injektionslösung 4 mg/kg BW, IV) were administered after 
surgery. 
4.6.4 Recovery phase and postoperative care 
Sixty minutes after ketamine administration, atipamezole (Antisedan ® Pfizer ad us vet., 
at the at the dose 2250 ?g/m2 (IM) (= time point 0) was administered. Animal 
observation and video recording were immediately started to assess behaviour and 
sedation, and continued for an hour. At time points 0, 10, 20, 30 and 60 assessment 
sedation and behaviour were performed. In addition, HR, pulse character RR, MMC and 
rectal temperature were recorded 0, 30 and 60 minutes after atipamezole 
administration.  
Sixty minutes after atipamezole administration, video recording stopped and the study 
was concluded. The video tape recordings were used to re-evaluate particular cases 
regarding the behavioural and sedation parameters. 
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4.6.5 Disposal of study animals 
During the same day of the surgery, all animals were returned to their owner 
respectively to the animal shelter. 
 
 
4.7 Handling of records 
4.7.1 Owner consent forms  
Owner consent forms (Annex A) were filled out and signed by the owner the day of the 
trial, before the beginning of the pre-operatory examination. 
4.7.2 Video Records.  
Each animals was filmed by the investigator: 
- Pre-operatory periods of 10 minutes were filmed (first 5 minutes without 
collar and then 5 minutes with collar). 
- Recovery period: the whole period between atipamezole administration 
(=time point 0) and the complete recovery (=time point 60) was filmed 
4.7.3 Case Reports Forms (CRF)  
4.7.3.1 Pre-admission examination (page 1 of 3): baseline clinical data 
- Date, CRF Number, group, ASA classification, patient data (name, owner, 
breed, age) 
- Pre-anaesthesia exam (pre-admission data measurement) 
- Body condition: weight, hydration status, body temperature) 
- Cardiovascular and respiratory system: respiratory rate, heart rate, 
mucous membrane colour, capillary refill time, pulse character, thoracic 
auscultation 
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Other systems and complementary information: 
- Concomitant drugs (yes/no) 
- Inclusion (yes/no) 
- Venous catheter (right/left) 
- Sedation: time, medetomidine and butorphanol doses, observations, heart 
rate, respiratory rate, pulse character, capillary refill time, mucous 
membrane colour 
4.7.3.2 Anaesthesia (page 2 of 3): anaesthesia monitoring (intraoperative data) 
- Anaesthesia induction: time, ketamine (A or B, dose), observations 
- Intubation: time, tubus size  
- Constant anaesthesia monitoring: time, O2 Flow, HR, SAP, DAP, MAP, 
RR, SpO2 %, MMC, CRT, End tidal CO2 , eyelid reflex (+/-), body position, 
observations 
- Surgery beginning time, surgery ending time 
- Application of lidocaine, carprofen and atipamezole doses 
- Atipamezole injection time (=Time point 0) 
- Ketamine re-dosing (Yes/no, dose) 
4.7.3.3 Recovery (page 3 of 3): Post operative data measurement 
During recovery of the first dog (CRF 1), the degree of sedation and the behaviour 
rapidly changed within the first 20 minutes. It was decided, that more measurements 
would be necessary during this period. Therefore the case report form was changed and 
future measurements (sedation, behaviour, vocalisations, muscle tone, eyes 
movements, tongue movements and salivation) were recorded for time points 0, 10, 20, 
30 and 60. The case report forms were adapted accordingly. The records of 
cardiovascular data at time points 0, 30 and 60 remained unaltered. Extubation time 
was also recorded and added on the case report form for anaesthesia monitoring. 
- Clinical examination at time point 0, 30, 60 minutes after reversal of 
anaesthesia (RR, mucous membrane colour, HR, capillary refill time, 
pulse character). Body temperature was assessed at time points 0 ad 60. 
- Assessment of sedation at time points 0, 10, 20, 30, 60 after atipamezole 
administration (Table 2). 
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Table 2: Sedation scores 
 
No sedation 0 Fully alert, reacting to noises 
 
Poor sedation 1 Alert but with somnolence, reacting to noises 
 
Moderate sedation 2 Drowsy but occasionally restless 
 
Deep sedation 3 Sleeping comfortable 
- Evaluation of behaviour at time points 0, 10, 20, 30, 60 minutes after 
atipamezole administration, scaled on the basis of the particular case and 
the clinical judgement of the investigator, as follows: 
• Clinical observations: eyes (myosis, mydriasis, third eye lid 
prolapsed, eye rolled ventrally, nystagmus) muscles (relaxation, 
tone increased, stiffness, tremor), tongue movements, presence or 
absence of salivation.  
• Other clinical signs not listed on the form, but relevant to the 
investigator were recorded also.  
• Time to sternal recumbency, time to standing position. 
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5. Data analysis 
5.1 Statistical methods 
NCSS 2004 (Kaysville, Utah, USA) software package was used to perform the statistical 
evaluation.  
- All data were analysed for normal distribution with the Shapiro-Wilk W test.  
- The significance of difference between groups for parametric data was 
assessed with Student’s t-tests or with ANOVA for data with more than two 
levels of significance.  
- Non-parametric variables were evaluated using Mann-Whitney U or 
Kurskal-Wallis tests.  
- Proportions were analysed with Chi-squared tests.  
- For all tests, overall P < 0.05 was considered the minimum level of 
statistical significance.  
- A trend towards a statistical significance was defined as P = 0.1. 
- Parametric data are presented as mean ± SD and non-parametric data are 
presented as mean, median and range and/or box plots.
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6. Results 
6.1 Animal details (population description): Pre-anaesthesia data 
6.1.1 Animal species and breeds 
The dog breeds, included in Table 3, were included into the study. 
Table 3: Breeds included in the study 
 
Breed Frequency Percentage 
American Staffordshire 2 2.4 
Border Collie 4 9.75 
Chinese crested hairless 1 2.4 
Dalmatian 1 2.4 
Dogo argentine 1 2.4 
Épagneul bleu de Picardie 1 2.4 
Labrador 3 7.3 
Lhassa Apso 1 2.4 
Pitt bull 1 2.4 
Rottweiler 1 2.4 
Shar pei 2 4.9 
Shi-Tzu 1 2.4 
Swiss white shepard 1 2.4 
Terrier du Tibet 1 2.4 
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Breed Frequency Percentage 
American Staffordshire 2 2.4 
Border Collie 4 9.75 
Chinese crested hairless 1 2.4 
Westhighland Terrier  2.4 
Mixed breed 22 53.7 
   
Total 41 100.0 
 
 
53.7 % of the dogs included in our study were by mixed breed’s dogs and the 
frequencies along our randomisation list showed us that no relevant statistical difference 
was present.  
6.1.2 Animal age 
Animal age was known in 35 of 41 dogs. For 2 dogs from animal shelter and 4 dogs 
from private owner, the exact age was unknown. The other dogs had a mean age of 2.1 
years (SD ± 1.5) with a minimum of 0.5 and a maximum of 7 years (Fig.13). 
The differences between the two groups were statistically irrelevant (p= 0.72). 
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Figure 13: Animal age in years 
 
6.1.3 Animal weight  
Dogs had a mean body weight of 24.0 kg (SD ± 9.9 kg), Fig.14.  
The differences between the two groups were statistically irrelevant (p=0.81). 
 
Figure 14: Animal weight in kg bodyweight 
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6.1.4 Heart rate (HR) 
Dogs (n=41) had, before sedation, a pre-operative mean heart rate of 77.7 beats / min 
(SD ± 17.8) with a minimum of 44.0 and a maximum of 120.0 beats/min.  
There was no statistical relevant difference between both groups (p= 0.86). 
6.1.5 Pulse character 
Three different categories (Table 4) were used in this study to describe the pulse 
character of the arteria femoralis: weak, normal and strong. Assessed by the principal 
investigator.  
Table 4: Pre-operative pulse characters 
 
 rac-ket group s-ket group 
Weak 0 (0.0%) 0 (0.0%) 
Normal 4 (20%) 4 (19%) 
Strong 16 (80%) 17 (81%) 
Total 20 (100%) 21 (100%) 
 
No statistical relevant differences were found between both groups (p = 0.94). 
6.1.6 Respiratory rate (RR) 
19 of 41 dogs were panting during pre-anaesthesia clinical examination. That's why 
respiratory rates were grouped into 3 categorical groups (Table 5) : 
- Category 1 included values between 1 and 30 breath/min; 
- Category 2 included values between 31 and 50 breath/min; 
- Category 3 included values above 50 breaths/min or panting; 
 
Table 5: Pre-operative respiratory rates 
 
 rac-ket group s-ket group 
Category 1 7 (35%) 9 (42.9%) 
Category 2 1 (5.0%) 5 (23.8%) 
Category 3 12 (60.0%) 7 (33.3%) 
Total 20 (100%) 21 (100%) 
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No statistical relevant differences were found between both groups (p = 0.12). 
6.1.7 Mucous membrane colour (MMC) 
Three different categories of MMC were used in the study: pale, pink (normal reference) 
and red. During the pre-operative examination just one dog in rac-ket group showed red 
mucous membranes, all others had pink mucous membranes. 
No statistical relevant differences were found between both groups (p = 0.29). 
6.1.8 Body temperature, capillary refill time (CRT), body condition, hydratation 
status and thoracic auscultation 
Body temperature was considered normal in 40 of 41 dogs. In one dog (CRF 12), 
belonging to rac-ket group, body temperature was elevated (39.6°C). As all other clinical 
parameters were normal and, as the dog didn't show any history of sickness, it was 
decided to include the dog in the study.  
One dog (CRF 10) belonging to rac-ket group had a slightly poor body condition; all 
others were considered to be of normal constitution. No abnormal thoracic auscultation 
finding was detected. Hydratation status was good in all dogs. Subjective evaluation of 
capillary refill time was considered adequate in all dogs: all values ranged between 1 
and 2 seconds. 
In conclusion, both groups were considered homogenous for pre-operative data. 
6.2 Intra operative data measurement 
The population of our study decreased from 41 to 37 dogs. Four dogs (CRF 2, 3, 15a 
and 22) all belonging to s-ket group were excluded from the study because 
supplemental ketamine was necessary in order to terminate elective surgery under good 
conditions. 
6.2.1 Heart Rate (HR) 
Heart rate was obtained in all dogs. Overall values were not significantly different 
between groups, although a trend was observed (p = 0.087) for higher heart rates in rac-
ket group (80.5 beats/min [45 -138]) compared with s-ket group (74 beats/min [35 -
134]). 
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Fig. 15: Mean intraoperative heart rates  averaged over time 
 
Over time, heart rates slightly decreased progressively in both groups. Values for heart 
rates were similar between groups, but a trend (p = 0.06) for higher heart rates in rac-ket 
group compared with s-ket group was found 25 minutes after ketamine administration 
(indicated on Fig.16 with ?). 
  
Fig. 16a: Mean Intra-operative heart 
rate values over time in rac-
ket group 
Fig. 16b: Mean Intra-operative heart 
rate values over time in s-ket 
group  
 
6.2.2 Respiratory Rate (RR) 
Respiratory rate was monitored in all dogs. There were no statistically significant 
differences (p = 0.22) between both randomisation groups (rac-ket group: 8 breaths/min 
[2-28]; s-ket group: 8 breaths/min [2-25]. 
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Fig. 17: Mean intra-operative respiratory rate values 
 
Shortly after ketamine administration, 3 dogs (CRF 5, 7 and 9) from rac-ket group 
showed apnoea that lasted for 30-40 seconds. In dogs CFR 5 and 7, spontaneous 
ventilation was reassumed after that short period of time and no assisted ventilation was 
required. In dog CFR 9 manual ventilation was necessary until spontaneous ventilation 
was restored at 5 minutes after ketamine administration.  
15 minutes after anaesthesia induction, respiratory rates increased progressively in both 
groups as evaluated by visual examination of the box plots. No differences were found 
between groups at any evaluated time point (p  > 0.05 for all time points). 
  
Fig. 18a: Mean intra-operative respiratory 
rate values over time in rac-ket group 
Figure 18b: Mean intra-operative 
respiratory rate values over time in s-ket 
group 
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6.2.3 End tidal CO2 (EtCO2) 
End tidal CO2 was obtained in all dogs. Values were significantly different (p = 0.006) 
between groups (rac-ket group = 40 mm Hg [15 - 88]; s-ket group = 36.5 mm Hg [8 -
58]).  
 
Fig. 19: Box plots for mean EtCO2 averaged over time  
Over time, results for EtCO2 were different between both groups: dogs in rac-ket group 
presented higher EtCO2 values than dogs in s-ket group during the first 10 minutes after 
anaesthesia induction (t=5 and t=10, p = 0.03 for both time points, indicated with on Fig. 
20 with the sign *). 
  
Fig. 20a: EtCO2 over time in rac-ket group Fig 20b: EtCO2 over time in s-ket group 
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6.2.4 Haemoglobin oxygen saturation (SpO2) 
Values for SpO2 were not significantly different (p = 0.69) between groups (median: 99% 
[81 -100] for both groups). Only 4 and 2 isolated readings below 90% were observed in 
rac-ket and s-ket group, respectively. 
 
Fig. 21: Box plots for mean) SpO2 averaged over time 
 
 
6.2.5 Indirect arterial blood pressure (DAP, MAP, SAP) 
Indirect arterial blood pressure was obtained in 14 out of 20 dogs in rac-ket group and in 
16 out of 17 dogs in s-ket group. 
Values for DAP were not significantly different (p=0.43) between groups (rac-ket group: 
median 84 mm Hg [30-174]; s-ket group, median: 86.5 mm Hg [14 -116]).  
Values for MAP were not significantly different (p=0.47) between groups (rac-ket group: 
median 100 mm Hg [42 -193]; s-ket group, median: 99 mm Hg [42 -140]).  
Values for SAP were not significantly different (p=0.82) between groups (rac-ket group: 
median 134 mm Hg [68 - 227]; s-ket group: median 133 mm Hg [87-174]). 
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Fig. 22a: Mean MAP over time in rac-ket group Fig. 22b: Mean MAP over time in s-ket group 
 
6.2.6 Capillary refill time 
Subjective evaluation of capillary refill time was considered adequate in all dogs. All 
values ranged between 1 and 2.5 seconds. 
6.2.7 Eyelid reflex 
There was a statistically significant difference in eyelid reflexes between groups 
(p=0.006) with more dogs showing positive eyelid reflexes in s-ket group than in rac-ket 
group. However, differences were not statistically significant when data were plotted 
over time and only a trend (p=0.09).for significant difference was found at 10 min 
(indicated with ? on Fig. 23a and Fig.23b). 
 
Fig. 23a: Eyelid reflexes over time in rac-ket group 
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Fig. 23b: Eyelid reflexes over time in s-ket group 
 
 
6.2.8 Adverse events during anaesthesia induction and maintenance until reversal 
with atipamezole 
- CRF 2,  CRF 3, CRF 15a: all belonging to the s-ket group needed 
supplemental bolus of ketamine (re-dosing). Those patients were excluded 
from the study.  
- CRF 5: belonging to the rac-ket group. 60 minutes after atipamezole 
administration the dog had diarrhoea once. No supplementary medication 
was necessary. The dog returned to the animal shelter. 
- CRF 6: belonging to the s-ket group, the patient was excluded for the 
evaluation of post-operative data because approximately 30 minutes after 
anaesthesia induction it started to show seizures-like episodes (only up-
down head movements) triggered by moving the dog from the operating 
room to the recovery room. Seizures were successfully treated with 5 mg 
intravenous diazepam, physiologic saline solution and nasal oxygen 
insufflations. Half an hour later the patient was re-sedated with 0.02 mg/kg 
acepromazine and 0.2 mg/kg butorphanol IV. The dog recovered without 
sequelae. This adverse event was announced to Swissmedic in line with 
the pharmacovigilance System of Dr. E. Graeub AG. 
- CRF 18: belonging to the rac-ket group was excluded for the evaluation of 
post-operative data because 31 minutes after anaesthesia induction, it 
started to show seizures-like episodes (only short up-down head 
movements), triggered by moving the dog from operating room to recovery 
room. The dog was treated with 5 mg intravenous diazepam. The dog 
recovered without sequelae.  
- CRF 22 belonging to the rac-ket group needed supplemental bolus of 
ketamine (re-dosing). This patient was excluded from the study. The dog 
recovered without sequelae. 
All dogs recovered well and safely and were returned save at home or to the local 
animal shelter the same day of the surgery. 
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6.3 Recovery 
Overall, all dogs recovered well from anaesthesia and returned home at the end of the 
experiment. Two dogs CRF 6, belonging to s-ket group and CRF 18 belonging to rac-ket 
group were excluded from evaluation of post-operative data because they had seizures-
like episodes approximately 30 minutes after ketamine administration and received 
supplemental medication that influenced the anaesthesia. 
No statistically significant differences between groups regarding mucous membrane 
colour, capillary refill time, body temperature and pulse quality (Table 6) were detected 
during recovery. Thoracic auscultation was considered normal in all dogs. 
Table 6: Pulse quality at recovery 
 
Pulse  rac-ket group 
n= 19 
s-ket group 
n=19 
p-value 
T=0 Weak  0 (0.0%) 0 (0.0%)  
0.68  Normal 12 (63.2%) 9 (56.3%) 
 Strong 7 (36.8%) 7 (43.7%) 
 
T=30 Weak 0 (0.0%) 0 (0.0%)  
0.75  Normal 14 (73.7%) 11 (68.8%) 
 Strong 5 (26.3%) 5 (31.2%) 
 
T=60 Weak 0 0.0%) 0 (0.0%)  
0.97  Normal 12 (63.2%) 10 (62.5%) 
 Strong 7 (36.8%) 6 (37.5%) 
 
6.3.1 Heart Rate 
On average, over time, there was a trend (p = 0.056) for higher heart rate values in dogs 
allocated to rac-ket group (median 64 beats/min [28-140]) compared to those in s-ket 
group (median 60 beats/min [36-120]). 
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Fig. 25: Box plots of post-operative median heart rate values 
averaged over time 
 
Over time, both groups showed a significant increase in HR values (p  0.001), after 
atipamezolde injection, but no significant differences were evident between groups at 
each time point.  
 
Fig. 26a: Post-operative heart rate 
values over time in rac-ket 
group after atipamezole 
administration 
Fig. 26b: Post-operative heart rate 
values over time in s-ket 
group after atipamezole 
administration 
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6.3.2 Respiratory rate 
Overall, both groups had similar (p = 0.33) respiratory rate values during the recovery 
period (rac-ket group: median: 5 breaths/min [2-32]; s-ket group median: 5 breaths/min 
[3-32]). Over time, RR values significantly (p = 0.001) decreased in both groups. No 
significant differences were detected between groups at each evaluated time point. 
 
Fig. 27a: Mean Post-operative 
respiratory rates over time 
in rac-ket group 
Fig. 27b: Mean Post-operative 
respiratory rates over time 
in s-ket group 
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6.3.3 Sedation 
Sedation scores were taken just after the administration of atipamezole (t=0), and 10 
(t=10), 20 (t=20), 30 (t=30) and 60 minutes (t=60) after atipamezole administration.  
Overall distributions of sedation values were comparable between groups (p = 0.97). 
Similarly, there were no statistically significant differences in regards to sedation values 
at each evaluated time point. 
Table 7a: Sedation scores at time just after atipamezole administration (=time point 0) 
 
 No 
sedation 
Poor 
sedation 
Moderate 
sedation 
Deep 
sedation 
Total p-value 
rac-ket 0 (0.0%) 2 (10.5%) 1 (5.3%) 16 (84.2%) 19 (100%)  
0.72 s-ket 0 (0.0%) 2 (12.5%) 2 (12.5%) 12 (75.0%) 16 (100%) 
Total 0 (0.0%) 4 (11.4%) 3 (8.6%) 28 (80.0%) 35 (100%) 
 
 
 
Table 7b: Sedation scores at 10 minutes after atipamezole administration (= time point 10) 
 
 No 
sedation 
Poor 
sedation 
Moderate 
sedation 
Deep 
sedation 
Total p-value 
rac-ket 9 (47.4%) 6 (31.6%) 4 (21.1%) 0 (0.0%) 19 (100%)  
0.71 s-ket 8 (50.0%) 4 (25.0%) 3 (18.8%) 1 (6.3%) 16 (100%) 
Total 17 (48.6%) 10 (28.6%) 7 (20.0%) 1 (2.9%) 35 (100%) 
 
 
 
Table 7c: Sedation scores at 20 minutes after atipamezole administration (= time point 20) 
 
 No 
sedation 
Poor 
sedation 
Moderate 
sedation 
Deep 
sedation 
Total p-value 
rac-ket 16 (84.2%) 3 (15.8%) 0 (0.0%) 0 (0.0%) 19 (100%)  
0.78 s-ket 14 (87.5%) 2 (12.5%) 0 (0.0%) 0 (0.0%) 16 (100%) 
Total 30 (85.7%) 5 (14.3%) 0 (0.0%) 0 (0.0%) 35 (100%) 
 
 
Table 7d: Sedation scores at 30 minutes after atipamezole administration (= time point 30) 
 
 No 
sedation 
Poor 
sedation 
Moderate 
sedation 
Deep 
sedation 
Total p-value 
rac-ket 19 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 19 (100%)  
 s-ket 16 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 16 (100%) 
Total 35 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 35 (100%) 
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Table 7e: Sedation scores at 60 minutes after atipamezole administration (= time point 60) 
 
 No  
sedation 
  Poor 
sedation 
Moderate    
 sedation 
Deep 
   sedation 
Total p-value 
rac-ket  19 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 19 (100%)  
 s-ket  16 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 16 (100%) 
Total 35 (100%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 35 (100%) 
 
 
 
 
Sedation scores over time: 
  
Fig. 28a: Sedation scores over time in rac-ket 
group 
Fig 28b: Sedation scores over time in s-ket 
group 
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6.3.4 Times to sternal and standing position 
There were no statistical differences in regard to time to first movement (p=0.09), time to 
sternal position (p=0.36) and time to sitting position (p=0.94) between both groups 
(Table 8).  
Table 8: Mean times to first movement, sternal position and sitting position and ranges.  
 
  N overall rac-ket group s-ket group p-value 
Time to first movement Min 35 3.9 [0-13.8] 3.7 [0-8] 5.35 [0.2-13.8] 0.09 
Time to sternal position Min 35 5.8 [0.8-27.9] 5.7 [1.2-24.3] 6.95 [0.8-27.9 ] 0.36 
Time to sitting position* Min 33 11.5 [1.2-47.8] 11.3 [1.2-47.8] 11.9 [5.3-28 ] 0.94  
 
*In the case that dogs went directly from sternal to standing position, without ever staying in a sitting 
position, time to achieve standing position was considered and included for calculation of "time to 
sitting position". 
 
 
 
 
 
Fig. 29: Mean anaesthesia recovery times 
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6.3.5 Behaviour 
Overall, distributions of behaviour scores were not significantly different between groups 
(p = 0.57). Similarly, there were no statistically significant differences in regards to 
behaviour scores at each evaluated time point (Table 9). 
Table 9a: Behavioural scores just before atipamezole administration (=time point 0) 
 
 Normal 
 
Minor 
    changes 
Moderate 
changes 
Severe 
changes 
Total p-value 
rac-ket 17 (89.5%) 1 (5.3%) 1 (5.3%) 0 (0.0%) 19 (100%)  
0.56 s-ket 14 (87.5%) 1 (6.3%) 0 (0.0%) 1 (6.3%) 16 (100%) 
Total 31 (88.6%) 2 (5.7%) 1 (2.9%) 1 (2.9%) 35 (100%) 
 
 
 
Table 9b: Behavioural scores 10 minutes just before atipamezole administration (= time point 
10) 
 
 Normal 
 
Minor 
    changes 
Moderate 
changes 
Severe 
changes 
Total p-value 
rac-ket 1 (5.3%) 11 (57.9%) 7 (36.8%) 0 (0.0%) 19 (100%)  
0.32 s-ket 3 (18.8%) 6 (37.5%) 7 (43.8%) 0 (0.0%) 16 (100%) 
Total 4 (11.4%) 17 (48.6%) 14 (40.0%) 0 (0.0%) 35 (100%) 
 
 
 
Table 9c: Behavioural scores 20 minutes just before atipamezole administration (= time point 
20) 
 
 Normal 
 
Minor 
    changes 
Moderate 
changes 
Severe 
changes 
Total p-value 
rac-ket 3 (15.8%) 13 (68.4%) 3 (15.8%) 0 (0.0%) 19 (100%)  
0.55 s-ket 3 (18.8%) 8 (50.0%) 4 (25.0%) 1 (6.3%) 16 (100%) 
Total 6 (17.1%) 21 (60.0%) 7 (20.0%) 1 (2.9%) 35 (100%) 
 
 
Table 9d: Behavioural scores 30 minutes just before atipamezole administration (= time point 
30) 
 
 Normal 
 
Minor 
    changes 
Moderate 
changes 
Severe 
changes 
Total p-value 
rac-ket 6 (31.6%) 11 (57.9%) 1 (5.3%) 1 (5.3%) 19 (100%)  
0.81 s-ket 6 (37.5%) 9 (56.3%) 0 (0.0%) 1 (6.3%) 16 (100%) 
Total 12 (34.3%) 20 (57.1%) 1 (2.9%) 2 (5.7%) 35 (100%) 
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7. Discussion 
Early human studies of ketamine isomers (White et al., 1980) appeared to demonstrate 
that the S (+) ketamine produces less psychic emergence reactions than the R (-) 
ketamine or the racemic mixture. Moreover, the S (+) ketamine in humans, horses and 
cats has proven advantageous by reaching an identical plane of anaesthesia with half of 
the racemic dose. 
7.1 Pre-anaesthesia data 
All dogs were considered healthy on the basis of a pre-admission examination 
performed pre-operatively. In one dog, body temperature was elevated, but as all other 
clinical parameters were normal, it was included in the study. The elevated temperature 
had no relevant negative impact on the anaesthesia procedure. Both groups were 
considered homogenous for the pre-operative data. 
7.2 Sedation  
In the present study the dogs were sedated by using the combination of an alfa-2 
adrenoceptor agonist (medetomidine) and butorphanol.  
Although the coadministration of drugs might have a significant impact on metabolism of 
ketamine enantiomers in cats and dogs (Balmer et al., 2008; Larenza et al. 2008; 
Baumgartner et al., 2002), the combination of medetomidine with butorphanol is clearly 
indicated as stated in the study of Ko et al. (2000).  
7.3 Induction with Ketamine 
Thirty minutes after administration of medetomidine and butorphanol, both ketamine 
solutions – racemic ketamine and S (+) ketamine – were administered intravenously.  
In the current study used a dose of 2 mg per kg BW of S (+) ketamine (s-ket group) and 
4 mg/kg BW of racemic ketamine (rac-ket group). These doses were considered 
equipotent and chosen based on preliminary data collected in sedated dogs and on data 
of other species. Similar doses have been successfully applied to cats (Larenza et al., 
2008; Balmer et al., 2005; Baumgartner et al., 2002; Stelter et al., 2001) and horses 
(Larenza et al., 2007).  
The dose rates chosen here are in contrast with the study of Duque et al. (2008), where 
a dose reduction of 50% of S (+) ketamine in comparison to racemic ketamine didn’t 
suggest equipotent anaesthetic effects in dogs. However in this study the authors did 
only apply racemic vs. S (+) ketamine during their trial (a) without the combination of 
other drugs and also (b) with clearly higher doses of ketamine (9 mg/kg for the racemic 
ketamine and respectively 6 mg per kg BW for the S (+) ketamine.   As the sole use of 
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ketamine is causing muscular spasms it is unethical to use it in this way in clinical 
cases. 
7.4 Intra-operative data 
Heart rate. Heart rates were not significantly different between both groups, but dogs in 
rac-ket group had slightly higher heart rates than dogs receiving S (+) ketamine. Over 
time, heart rates slightly decreased in both groups. Graf et al. (1995) reported, using the 
isolated perfused heart model, that  S (+) ketamine is less depressant compared to 
racemic and isomeric R (-) ketamine.  
Intra-operative values for arterial blood pressure and capillary refill time were within 
normal ranges in all dogs and no differences were detected between both groups.  
Respiratory function. After ketamine administration, 3 dogs from rac-ket group showed 
apnoea. In one dog manual ventilation was necessary. Over time, respiratory rates 
progressively increased in both groups. Ketamine is one of the most reliable anaesthetic 
agent for anaesthesia induction and maintenance, since at clinically useful dose rates it 
does not or only mildly impair respiration (Paix et al., 2005; Werner et al., 1997). The 
transient apnoea induced by ketamine appears to be dose dependent. At higher doses, 
respiration is characterised by an apneustic, shallow, and irregular pattern (Sears, 
1971). Severe depression or arrest with over dosage has been described in humans 
and cats (Kopman, 1972; Child et al., 1972; Bree et al., 1972). In the present report the 
fact that only in the racemic ketamine group apnoea occurred might suggest, that the 
dose rate used was slightly more potent than the one of the S-ketamine group. This is 
also supported by the fact, that end tidal carbon dioxide concentration was significantly 
higher in rac-ket group than in s-ket group during the first 10 minutes after anaesthesia 
induction . Even if all values were within acceptable ranges, this result could be an 
indication for better alveolar ventilation in s-ket group, at the dose ranges tested.  
Metabolism/duration of action of ketamine. After surgery 3 dogs from S-ket group (S 
(+) ketamine) were excluded from the study because ketamine re-dosing (supplemental 
bolus) was necessary to complete the routine orchiectomy. Differences in ketamine 
action could originate from the pharmacokinetics (absorption, bioavaibility, distribution, 
metabolism and elimination), from pharmacodynamics (number of receptors, subtypes 
of receptors, affinity to receptors) or both (Duque et al., 2008).  In the case of S-
ketamine it is most likely a pharmacokinetic phenomenon. When administered as a sole 
agent in men and dogs, the plasmatic clearance of S (+) ketamine is higher than that of 
the R (-) ketamine and than that of the S (+) ketamine given in the racemic form (Ihmsen 
et al., 2001; Henthorn et al., 1999). Another contributing factor is that the 2 isomers 
compete for the same enzymatic complex in the liver (Kharasch and Labroo, 1992) 
reducing the rate of its metabolism when administered in the form of the racemate. In 
the study of Larenza et al. (2008) the elimination rate was significantly higher and 
elimination half-life and mean residence time were lower for S (+) ketamine after S (+) 
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ketamine compared to racemic ketamine administration. As the action of the dose of S-
ketamine tested here was a bit too short in all dogs to allow castration, a constant rate 
infusion of the drug could follow the initial bolus and like this anaesthesia duration could 
be extended safely. In the present report the relevant dogs were successfully castrated 
with a further bolus. Their cardiopulmonary and recovery data however was excluded 
from the study. 
For recovery medetomidine’s action was antagonised by its antagonist atipamezole 1 h  
after the initial ketamine application. At the dose rates of medetomidine tested otherwise 
recovery would have been delayed. Medetomidine pharmacokinetics in cats and dogs 
are characterized by a peak concentration after IM administration within 0.5 h.  
Elimination of medetomidine from plasma/serum occurred with half-lives ranging from 
0.97 to 1.60 h. (Salonen,1989). As the dogs recovered thereafter quickly and smoothly it 
is unlikely, that there was still significant residual action of either ketamine. 
Convulsions. Two dogs, one belonging to s-ket group and one belonging to rac-ket 
group suffered from seizures-like episodes approximately 30 minutes after ketamine 
administration. Both dogs were treated with benzodiazepines which stopped the 
seizures immediately. However were these two dogs data excluded from evaluation of 
post-operative data because they received supplemental medication that influenced the 
anaesthesia. Convulsions during anaesthesia of dogs have multiple causes (Lervik et 
al., 2010). Ketamine at higher doses has been associated with convulsions, increased 
muscle tone and spontaneous muscular activity in dogs (Haskins et al. 1985). Both 
patient recovered well from anaesthesia and were returned to their respective owner the 
same day of surgery. 
7.5 Recovery 
Overall there were no differences between the two groups concerning recovery.  
Assessment of behaviour. The behavioural changes after racemic ketamine are well 
known and have been the reason for reluctance of many practitioners to administer such 
a drug to their patients (Kohr and Durieux, 1998). Typical ketamine effects on behaviour, 
are: ataxia, increased motor activity, hyperreflexia, hallucinations (dogs are like 
“watching butterflies”), head movements, tongue movements and increased saliva 
production. In previous studies in dogs, the use of S (+) ketamine anaesthesia resulted 
in the shorter duration of unconsciousness, shorter time to sternal recumbency (TSR) 
and more quiet recovery from anaesthesia when compared to racemic ketamine (Muir 
and Hubbell, 1988). The application of a smaller dose of S (+) ketamine, in comparison 
with racemic ketamine, produced a faster recovery from anaesthesia with a minor 
incidence of psychomimetic side effects, at similar cardiovascular effects during 
anaesthesia (Oleskovicz et al., 2009; de Almeida et al., 2005; Duque et al., 2004). In the 
present study all dogs were sedated with medetomidine. There were no statistical 
differences in regard to time to first movement (p = 0.09), time to sternal position (p = 
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0.36) and time to sitting position (p = 0.94) between both groups.  In contrast with 
previous studies in cats and dogs, in the present study no statistical differences were 
found. Differences between racemic ketamine and S (+) ketamine were  probably 
masked by medetomidine’s strong sedative action. Following its reversal, 60 minutes 
after the application of the ketamine, sedation and behaviour scores at all time points 
were similar between both groups, as the effects of either ketamine had vanished by 
then.  
Diarrhoea. One dog, 60 minutes after atipamezole administration, showed once a 
diarrhoea episode.  There are multiple causes for diarrhoea episodes during the post-
operative phase in dogs including stress, NSAID and concomitant not reported disease. 
Because the animal shelter’s keepers reported no new episodes of diarrhoea in the 
following 5 days, a concomitant disease vs. cause can be excluded.  
The peri-operative procedure includes many possible stressors (dogs belonging to the 
animal shelter, environmental factors at the clinic and recovery quality). The importance 
of the different individual responses is not evaluable, in fact pre-operative stress effects 
during the whole peri-operative period and especially the post-anaesthetic recovery 
phase are still understudied (Väisänen et al., 2005) 
NSAIDs can provoque an acute as well as a chronic toxicosis. Toxicosis are usually 
manifested by gastrointestinal upset including: nausea, vomiting, haemorrhage and 
ulceration (Raekallio et al. 2006; Vollmar, 1993). Dogs are especially sensitive to those 
drugs, and reports of serious, and occasionally fatal, complications are numerous. 
Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and 
antipyretic activity. In animals, carprofen is as potent as indomethacin and more potent 
than aspirin or phenylbutazone, but appears to be safer than most other NSAIDs (Fox et 
al., 1997; Papich, 1997).  In a study on effects of short-term sequential administration of 
NSAID drugs (carprofen and deracoxib) on the stomach and proximal portion of the 
duodenum in healthy dogs, lesion worsening from day before were observed after day 
2. But none of the tested drugs did cause clinically important gastro-duodenal ulcers 
(Dowers et al., 2006). In our study all dogs were treated with a single injection of 
carprofen at the dose of 4 mg/kg BW immediately after the end of surgery. Therefore it 
is unlikely that carprofen alone caused important lesions or symptoms but in 
combination with stress it might help to cause diarrhoea. 
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8. Conclusion 
The main goal of the present study was to compare safety and effectiveness of 
anaesthesia (induction, maintenance and recovery qualities) in dogs undergoing elective 
neutering surgery, anaesthetised with racemic ketamine and with S (+) ketamine, at half 
the dose rate of the racemic ketamine. At these doses, both groups showed a 
comparable degree of intra-operative anaesthesia. The fact, that two dogs in the S (+) 
ketamine needed re-dosing might indicate, that duration of action of S (+) ketamine at 
the tested dose rates is slightly shorter than the one of the racemic ketamine, as shown 
for other species before. In compromised patients and older patients this is certainly an 
advantage of S (+) ketamine over racemic ketamine. At the tested dose ranges 
respiration was better maintained with S (+) ketamine, which in practice is another 
important factor to increase safety. 
Taking all together, it is concluded that male dogs undergoing routine neutering surgery 
and anaesthetised with a single dose of intravenous S (+) ketamine showed acceptable 
intra-operative anaesthetic conditions with post-anaesthetic parameters within the 
physiological range similar to those of racemic ketamine by the use of only 50% of the 
dose. S (+) ketamine has been demonstrated to be safe and effective for induction, 
maintenance and recovery of short anaesthesia in dogs sedated with medetomidine 
undergoing surgical castration.  
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Annex C: Others drugs used in both groups 
Medetomidine 
Medetomidine: dose 450 ?g/m2 BSA (body surface area), used intramuscularly (IM), 
trade name Dorbene ® ad us. vet., Injektionslösung Dr. E. Graeub AG, Bern, Switzerland 
Butorphanol 
Butorphanol: dose 0.2 mg/kg BW, used intramuscularly (IM), trade name Morphasol-10 ® 
ad us. vet., Injektionslösung Dr. E. Graeub AG, Bern, Switzerland 
Atipamezole 
Atipamezole: dose case by case; 2250 ?g/m2 BSA; used intramuscularly (IM); trade 
name Antisedan ® ad us. vet., Injektionslösung; Pfizer AG, Zürich, Switzerland 
Carprofen  
Carprofen: dose 4 mg/kg BW, used intravenously (IV); trade name Rimadyl ® ad us. vet., 
Injektionslösung; Pfizer AG, Zürich, Switzerland 
Amoxicillin / clavulanate 
Amoxicillin and clavulanate: dose 8.75 mg/kg BW, used subcutanously (SC); trade 
name Synulox Suspension ®, ad us. vet., Injektionssuspension Pfizer AG, Zürich, 
Switzerland 
Lidocaine 
Lidocaine: dose 1 mg/kg BW, trade name Lidocain 2% ®; Chassot ad us. vet., 
Injektionslösung Vetoquinol AG, Switzerland 
 
